The Antibiotic Arms Race: Current and Emerging Therapy for Klebsiella pneumoniae Carbapenemase (KPC) – Producing Bacteria.

Related Articles

The Antibiotic Arms Race: Current and Emerging Therapy for Klebsiella pneumoniae Carbapenemase (KPC) - Producing Bacteria.

Expert Opin Pharmacother. 2018 Oct 22;:

Authors: Plazak ME, Tamma PD, Heil EL

Abstract
INTRODUCTION: The rapid spread of Klebsiella pneumoniae Carbapenemase (KPC)-producing bacteria comprises one of the greatest challenges to global health. Historically, clinicians were limited to therapies with suboptimal efficacy and intolerable toxicity until the FDA approved ceftazidime-avibactam and meropenem-vaborbactam, adding two essential pharmacotherapies to our antibiotic armamentarium. These agents display superior efficacy and safety compared to historical treatment options; however, resistance has already been reported. Several antimicrobials currently in the drug pipeline exhibit early promise and may fill needed gaps in therapy. Areas covered: This article encompasses both the past and present treatment options for the management of KPC-producing bacterial infections via an extensive review and critical appraisal of the current literature. Expert opinion: Traditional treatment options can no longer be recommended as first-line options for the management of KPC-producing bloodstream infections (BSIs). Ceftazidime-avibactam or meropenem-vaborbactam plus or minus an aminoglycoside or polymyxin should be utilized as backbone therapies given their superior efficacy and safety profiles when compared to traditional treatment options. For susceptible KPC-producing urinary tract infections, it is reasonable to consider treatment with an aminoglycoside or with fosfomycin as a monotherapy. All of these decisions should be based on patient specific characteristics, severity of infection and source control, susceptibility patterns, and input from infectious diseases experts.

PMID: 30346216 [PubMed - as supplied by publisher]